Is Tolvaptan covered by medical insurance?

Tolvaptan tablets (Tolvaptan), the original drug, has been approved by the State Food and Drug Administration for sale in China and sold under the trade name Sumaika. It was subsequently included in the scope of Class B medical insurance through the medical insurance standards of the National Medical Insurance Bureau. However, the reimbursement ratios are different in different regions, and the price after reimbursement will be different. Domestic pharmacies or hospitals will sell this drug. There are also domestic drugs produced by other pharmaceutical companies in China, and their drug ingredients are basically the same.

Tolvaptan phosphate is a prodrug of tolvaptan, originally developed for intravenous administration. After administration, tolvaptan phosphate is converted into the active drug tolvaptan in the human body. Tolvaptan tablets are indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia and for the treatment of slowly declining renal function in adults at risk for rapidly progressive autosomal dominant polycystic kidney disease (ADPKD). Tolvaptan tablets should not be used for more than 30 days and should not be used in patients with underlying liver disease. It may cause liver damage and may lead to liver failure. When used to treat hyponatremia, it may cause hyponatremia to be corrected too quickly, causing fatal osmotic demyelination syndrome.

Tolvaptan tablets sold in China The price paid by medical insurance is relatively cheap, and the original drug of tolvaptan tablets sold overseas is sold under the trade namesSamsca, Jynarque, and also produced in other countries span>TolvaptanGeneric drugs, produced by Indian pharmaceutical factoriesThe price of each box of 15mg*4 tablets is around RMB 800 (the price may fluctuate due to exchange rates). The ingredients of foreign generic drugs are basically the same as those of domestic and foreign original drugs.